Type I results from mutations in the MYO5A gene and is characterized by primary neurological impairment including seizures and hypotonia, while immune-related features like susceptibility to infections and hemophagocytic syndrome (HLH) are not typically observed. This evidence concerns the gene MYO5A and hemophagocytic syndrome.